◆英語タイトル:Novan Inc (NOVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9954
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Novan Inc (Novan) is a clinical-stage pharmaceutical company that develops nitric oxide therapies for the treatment of dermatological and oncovirus-mediated diseases. The company’s pipeline products are being developed for the treatment of acne vulgaris; genital warts; for onychomycosis and for treatment of psoriasis and atopic dermatitis. Novan uses its proprietary technology Nitricil, to customize macromolecular delivery of nitric oxide and store gaseous species which result in nitric oxide-releasing new chemical entities for healthcare applications. The company’s products find application in the treatment of dermatology disorders. It works in collaboration with academic institutions, public and private companies and other universities. Novan is headquartered in Morrisville, North Carolina, the US.
Novan Inc (NOVN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Novan Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novan Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Novan Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novan Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Novan Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Novan Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Novan Acquires Intellectual Property Rights From KNOW Bio 11
Venture Financing 12
Novan Raises Additional USD2.4 Million in Venture Financing 12
Novan Raises USD30.4 Million in Financing Round 13
Novan Raises Additional USD39.7 Million in Venture Financing 14
Novan Raises USD10.3 Million in Venture Financing 15
Novan Raises USD3.5 Million in Venture Financing 16
Novan Raises US$11 Million In Series D Financing 17
Licensing Agreements 18
Sato Pharma Amends Licensing Agreement with Novan 18
Know Bio Enters into Sub-Licensing Agreement with Novan 20
Know Bio Enters into Licensing Agreement with Novan 21
Novan Enters into Licensing Agreement with University of Akron Research Foundation 22
Equity Offering 23
Novan Raises USD38 Million in Public Offering of Shares 23
Novan Plans to Raise Funds through Public Offering of Shares 24
Novan Raises USD51.9 Million in IPO 25
Novan Inc – Key Competitors 26
Novan Inc – Key Employees 27
Novan Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
May 12, 2017: Novan Reports First Quarter 2017 Financial Results 29
Mar 20, 2017: Novan Reports Fourth Quarter and Full Year 2016 Financial Results 30
Corporate Communications 32
Apr 12, 2018: Novan Advances Organization and Strengthens Leadership Team 32
Feb 21, 2018: Dr. Eugene Sun Appointed to Novan Board of Directors 33
Jan 19, 2018: Novan Announces Resignation Of William L. Hodges As Interim Chief Financial Office 34
Sep 26, 2017: Machelle Sanders Appointed to Novan Board of Directors 35
Aug 16, 2017: Novan Appoints Paula Brown Stafford, Chief Development Officer, to Board of Directors 36
Jun 05, 2017: Novan Announces Leadership Adjustments and Business Update 37
Mar 22, 2017: Novan Reshapes Executive Management Team 39
Clinical Trials 41
May 17, 2018: SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment 41
Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference 42
Dec 05, 2017: Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414 44
Apr 27, 2017: Novan Presents Preclinical Data from Inflammatory Skin Diseases Program 45
Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47
List of Tables
Novan Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Novan Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novan Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Novan Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novan Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Novan Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Novan Acquires Intellectual Property Rights From KNOW Bio 11
Novan Raises Additional USD2.4 Million in Venture Financing 12
Novan Raises USD30.4 Million in Financing Round 13
Novan Raises Additional USD39.7 Million in Venture Financing 14
Novan Raises USD10.3 Million in Venture Financing 15
Novan Raises USD3.5 Million in Venture Financing 16
Novan Raises US$11 Million In Series D Financing 17
Sato Pharma Amends Licensing Agreement with Novan 18
Know Bio Enters into Sub-Licensing Agreement with Novan 20
Know Bio Enters into Licensing Agreement with Novan 21
Novan Enters into Licensing Agreement with University of Akron Research Foundation 22
Novan Raises USD38 Million in Public Offering of Shares 23
Novan Plans to Raise Funds through Public Offering of Shares 24
Novan Raises USD51.9 Million in IPO 25
Novan Inc, Key Competitors 26
Novan Inc, Key Employees 27
List of Figures
Novan Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Novan Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Novan Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Novan Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Novan Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novan Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Novan Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novan Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9